M
Mario Tiribelli
Researcher at University of Udine
Publications - 257
Citations - 4895
Mario Tiribelli is an academic researcher from University of Udine. The author has contributed to research in topics: Myeloid leukemia & Imatinib mesylate. The author has an hindex of 34, co-authored 231 publications receiving 4170 citations. Previous affiliations of Mario Tiribelli include University of Trieste & Misericordia University.
Papers
More filters
Journal ArticleDOI
Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia
Simona Soverini,Sabrina Colarossi,Alessandra Gnani,Gianantonio Rosti,Fausto Castagnetti,Angela Poerio,Ilaria Iacobucci,Marilina Amabile,Elisabetta Abruzzese,Ester Orlandi,F. Radaelli,Fabrizio Ciccone,Mario Tiribelli,Roberto Di Lorenzo,Clementina Caracciolo,Barbara Izzo,Fabrizio Pane,Giuseppe Saglio,Michele Baccarani,Giovanni Martinelli +19 more
TL;DR: P-loop and T315I mutations were particularly frequent in advanced-phase chronic myeloid leukemia and Ph+ ALL patients, and often accompanied progression from chronic phase to accelerated phase/blast crisis, and should warn the clinician to reconsider the therapeutic strategy.
Journal ArticleDOI
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Gianantonio Rosti,Francesca Palandri,Fausto Castagnetti,Massimo Breccia,Luciano Levato,Gabriele Gugliotta,Adele Capucci,Michele Cedrone,Carmen Fava,Tamara Intermesoli,Giovanna Rege Cambrin,Fabio Stagno,Mario Tiribelli,Marilina Amabile,Simona Luatti,Angela Poerio,Simona Soverini,Nicoletta Testoni,Giovanni Martinelli,Giuliana Alimena,Fabrizio Pane,Giuseppe Saglio,Michele Baccarani +22 more
TL;DR: Data support a role for nilotinib for the frontline treatment of CML, which has a higher binding affinity and selectivity for BCR-ABL with respect to imatinib and is an effective treatment of chronic myeloid leukemia (CML) afterImatinib failure.
Journal ArticleDOI
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study
Michele Baccarani,Daniela Cilloni,Michela Rondoni,Emanuela Ottaviani,Francesca Messa,Serena Merante,Mario Tiribelli,Francesco Buccisano,Nicoletta Testoni,Enrico Gottardi,Antonio De Vivo,Emilia Giugliano,Ilaria Iacobucci,Stefania Paolini,Simona Soverini,Gianantonio Rosti,Francesca Rancati,Cinzia Astolfi,Fabrizio Pane,Giuseppe Saglio,Giovanni Martinelli +20 more
TL;DR: All patients meeting the criteria for idiopathic or primary HES should be screened for the FIP1L1-PDGFRα rearrangement, and chronic imatinib treatment at doses as low as 100 mg daily ensures complete and durable responses.
Journal ArticleDOI
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).
Paola Secchiero,Paola Secchiero,Elisa Barbarotto,Elisa Barbarotto,Mario Tiribelli,Mario Tiribelli,Carlotta Zerbinati,Carlotta Zerbinati,Maria Grazia di Iasio,Maria Grazia di Iasio,Arianna Gonelli,Arianna Gonelli,Francesco Cavazzini,Francesco Cavazzini,Diana Campioni,Diana Campioni,Renato Fanin,Renato Fanin,Antonio Cuneo,Antonio Cuneo,Giorgio Zauli,Giorgio Zauli +21 more
TL;DR: The induction of p53 by nutlin-3 in B-CLL samples was accompanied by alterations of the mitochondrial potential and activation of the caspase-dependent apoptotic pathway and the profile of gene activation showed a partial overlapping with that induced by the genotoxic drug fludarabine.
Journal ArticleDOI
The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype
Daniela Damiani,Mario Tiribelli,Elisabetta Calistri,Antonella Geromin,Alexsia Chiarvesio,Angela Michelutti,Margherita Cavallin,Renato Fanin +7 more
TL;DR: BCRP over-expression did not influence the achievement of remission, but significantly affected the duration of complete remissions and may be regarded as a prognostic factor in patients with normal karyotype AML, for the design of risk-adapted post-remission therapy.